Status:
RECRUITING
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Lead Sponsor:
Ankyra Therapeutics, Inc
Conditions:
Advanced Solid Tumor
Cutaneous Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced sol...
Detailed Description
This Phase 1 first-in-human (FIH) study will: 1) evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects and preliminary clinical activity of tolododekin alfa (ANK-101) administ...
Eligibility Criteria
Inclusion
- ≥ 18 years of age on day of signing informed consent
- histologically or cytologically confirmed diagnosis of cutaneous, subcutaneous, soft tissue, or nodal advanced solid tumor malignancy; metastatic disease eligible
- measurable disease per RECIST v1.1 - Note: Must have at least 1 tumor lesion with longest dimension of ≥ 10 mm (≥ 15 mm for the short axis for malignant lymph node lesions) that - For Part 1 only: can be easily palpated or detected by ultrasound to facilitate IT injection of ANK-101 (i.e., tumor in skin, muscle, subcutaneous tissue, or accessible lymph node) or; - For Part 2 only: can be accessed by interventional radiologic or endoscopic procedures for injection (e.g., ultrasound or computed tomography \[CT\] guided). - For Part 2 Dose Expansion Cohort only: Histologically confirmed Stage III or Stage IV NSCLC
- Part 3 CSCC Combination Cohort: Histologically confirmed high-risk locally advanced or metastatic CSCC not amenable to surgical management as determined by a multidisciplinary tumor board.
- documented disease progression, be refractory to, or intolerant of existing SOC therapy(ies) known to provide clinical benefit (including surgical cure) or not be eligible for SOC therapy(ies)
- ECOG performance status 0-1
- life expectancy \> 12 weeks
- adequate bone marrow, hepatic and renal function
- baseline electrocardiogram (EKG) without evidence of acute ischemia or prolonged QTc interval \> 460 msec
- Human immunodeficiency virus (HIV) infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection/disease
- last dose of previous anticancer therapy (including investigational agents) ≥ 28 days, radiotherapy ≥ 14 days (targeted palliative radiotherapy is allowed for lesions not planned for injections), or surgical intervention ≥ 21 days prior to the start of treatment
- resolution of all prior anticancer therapy toxicities (except for alopecia or vitiligo) to ≤ Grade 1 (as per NCI CTCAE Version 5.0)
- willing to provide pre- and post-treatment tumor biopsy samples if medically feasible
- participant is capable of understanding and complying with protocol requirements
Exclusion
- injectable tumors impinging upon major airways or blood vessels
- prior treatment with recombinant interleukin-12 (IL-12)
- have received systemic therapy with immunosuppressive agents ≤ 28 days before the start of treatment
- have received live vaccines within 28 days prior to the start of ANK-101 treatment
- have primary or acquired immunodeficient states (e.g., leukemia, lymphoma)
- a woman of childbearing potential (WOCBP) who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment or female participant who is breastfeeding
- prior organ transplantation
- known history of hepatitis B virus, known active hepatitis C virus, or a positive serological test at screening within 28 days prior to the start of treatment
- HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease
- active autoimmune disease or medical conditions requiring chronic steroid (i.e., ≥ 20 mg/day prednisone or equivalent) or other immunosuppressive therapy within 28 days prior to the start of treatment
- known active central nervous system (CNS) metastases
- congestive heart failure (\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias
- uncontrolled bleeding disorders within 4 weeks prior to the start of treatment or known bleeding diathesis - Note: Part 2 only: Participants with active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
- history of hypersensitivity to compounds of similar biological composition to IL-12, aluminum hydroxide, or drugs formulated with polysorbate-20
- other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study
- any acute or chronic psychiatric problems or substance abuse disorder that, in the opinion of the Investigator, make the participant unsuitable for participation
- Part 3 only: prior Grade 3 or greater immune-mediated adverse events (imAEs) following treatment with an agent that blocks the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway.
- Part 3 only: hypersensitivity to cemiplimab or any of its excipients or contraindications to cemiplimab per approved local labeling
Key Trial Info
Start Date :
January 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT06171750
Start Date
January 19 2024
End Date
June 1 2027
Last Update
July 18 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Bethesda, Maryland, United States, 20892
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
Providence Cancer Institute
Portland, Oregon, United States, 97213
4
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232